Skip to content
Research/Regenerative Aesthetics/VEGF Plasmid

VEGF Plasmid

VEGF Plasmid therapy involves the use of plasmids to deliver vascular endothelial growth factor (VEGF) genes to promote angiogenesis and tissue regeneration. This approach aims to enhance blood vessel formation, which can be beneficial in wound healing and tissue repair, potentially improving longevity and health by supporting regenerative processes.

Intelligence Profile

Science

The VEGF plasmid therapy involves delivering a plasmid DNA encoding for Vascular Endothelial Growth Factor (VEGF), a protein that promotes angiogenesis, the formation of new blood vessels. This mechanism exploits the body’s natural processes to enhance blood supply to tissues that are ischemic or have reduced blood flow.

VEGF is known to play a critical role in both physiological and pathological angiogenesis. On a molecular level, once the VEGF plasmid is delivered into target cells, it utilizes the host cell's machinery to produce VEGF protein. This protein then interacts with specific receptors on the surface of endothelial cells, such as VEGFR-1 and VEGFR-2, which are primarily involved in the proliferation and migration of these cells, leading to new blood vessel formation.

Delivery Systems:

  • Use of nanoparticles: The study published in the International Journal of Pharmaceutics (PMID: 42508511) discusses using PLGA nanoparticles to deliver VEGF plasmids. These nanoparticles help target and release the plasmid into bone tissues, which may be beneficial for treating conditions like osteoporosis by enhancing local blood supply and supporting bone regeneration.

  • Core-shell fibrous threads: Another approach detailed in Biomedical Materials (PMID: 42372784) is using fibrous threads loaded with VEGF plasmid polyplexes. This method facilitates sustained gene delivery, ensuring continuous production of VEGF at levels that exceed a therapeutic threshold, especially useful in chronic ischemic conditions.

Clinical Applications:

  • Lower Extremity Ischemia: As discussed in Cells (PMID: 42346131), angiogenic gene therapy using VEGF plasmids has been tested experimentally and clinically to improve blood supply in ischemic lower extremities, addressing issues like intermittent claudication as shown in clinical trial NCT00080392.

  • Cardiac Angiogenesis: The NCT00620217 trial examines using the VEGF-A165/bFGF plasmid in patients with coronary artery disease. By enhancing angiogenesis, the therapy might offer an option for patients not eligible for other revascularization procedures.

In summary, VEGF plasmid therapy primarily acts by stimulating angiogenesis at a molecular level, addressing conditions with inadequate blood flow or tissue damage by leveraging targeted delivery systems to enhance therapeutic outcomes.

Disclaimer: This content is for informational purposes only and not intended as personalized medical advice. Always consult a healthcare professional for medical concerns.